4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
9.66
+1.34 (16.11%)
At close: Oct 8, 2025, 4:00 PM EDT
9.74
+0.08 (0.83%)
After-hours: Oct 8, 2025, 7:47 PM EDT
4D Molecular Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts that cover 4D Molecular Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $30.63, which forecasts a 217.08% increase in the stock price over the next year. The lowest target is $6.00 and the highest is $40.
Price Target: $30.63 (+217.08%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 12, 2025.
Analyst Ratings
The average analyst rating for 4D Molecular Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth Capital | Roth Capital | Strong Buy Maintains $44 → $38 | Strong Buy | Maintains | $44 → $38 | +293.37% | Aug 12, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +158.80% | Aug 12, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +158.80% | Aug 1, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +158.80% | Jul 3, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $28 → $25 | Strong Buy | Maintains | $28 → $25 | +158.80% | May 9, 2025 |
Financial Forecast
Revenue This Year
3.61M
from 37.00K
Increased by 9,656.76%
Revenue Next Year
3.40M
from 3.61M
Decreased by -5.73%
EPS This Year
-3.77
from -2.98
EPS Next Year
-3.85
from -3.77
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 21.0M | 21.0M | |||
| Avg | 3.6M | 3.4M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 56,656.8% | 481.7% | |||
| Avg | 9,656.8% | -5.7% | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.35 | -2.91 | |||
| Avg | -3.77 | -3.85 | |||
| Low | -3.90 | -4.66 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.